Home/Healthcare/Healthcare IT/Japan Continuous Glucose Monitoring (CGM) Market

Japan Continuous Glucose Monitoring (CGM) Market - Strategic Insights and Forecasts (2026-2031)

Market Analysis, Growth and Trends By Application Type (Diabetes Monitoring, Critical Patient Monitoring), and End-use Facility (Hospitals, Diagnostic Centers & Clinics, Homecare Settings)

Market Size in 2026
USD 400.0 million
Market Size in 2031
USD 944.7 million
CAGR
18.8%
Study Period
2021-2031
$3,350
Single User License
Report OverviewSegmentationTable of ContentsCustomize Report

Report Overview

The Japan Continuous Glucose Monitoring (CGM) market is forecast to grow at a CAGR of 18.8%, reaching USD 944.7 million in 2031 from USD 400.0 million in 2026.

Japan Continuous Glucose Monitoring (CGM) Market - Strategic Insights and Forecasts (2026-2031) market growth projection from $400.00M in 2026 to $944.70M by 2031 at a CAGR of 18.8%.
Japan Continuous Glucose Monitoring (CGM) Market - Strategic Insights and Forecasts (2026-2031) market growth projection from $400.00M in 2026 to $944.70M by 2031 at a CAGR of 18.8%.

Highlights:

  1. 1
    Diabetic patients actively using real-time CGM devices
    Individuals are continuously monitoring blood glucose levels for better daily diabetes management.
  2. 2
    Hospitals integrating advanced CGM systems
    Healthcare facilities are adopting continuous monitors to enhance patient care and outcomes.
  3. 3
    Government expanding reimbursement policies
    Authorities are supporting wider CGM access through new insurance coverage initiatives.
  4. 4
    Manufacturers launching innovative CGM sensors
    Companies are developing advanced technologies to improve accuracy and user convenience.
  5. 5
    Clinics offering CGM solutions
    Diagnostic centers are providing continuous glucose monitoring for effective diabetes treatment.
  6. 6
    Patients utilizing CGM smartphone applications
    Users are leveraging real-time apps to make informed decisions about diet and medication.

Japan Continuous Glucose Monitoring Market:

Continuous sugar monitoring (CGM), sometimes referred to as sugar continuous glucose monitoring, automatically monitors blood glucose throughout the day. Making more educated choices about maintaining daily medication use, a healthy diet, and physical activity can be aided with real-time glucose monitoring. A small sensor used in CGM is implanted beneath the skin, often on the arm or abdomen. The sensor picks up interstitial glucose, which is present in the intercellular fluid. The sensor examines the glucose level every few minutes, and wireless data transmission sends the results to a monitor.

Moreover, the closed-loop bionic/artificial pancreas has been given a blueprint because of CGMS-based technologies. Thus, businesses that manufacture glucose monitoring devices concentrate largely on creating novel and cutting-edge CGMS. It has several applications for healthcare settings (hospital ICUs, diagnostic centers, and clinics), for all age groups, and geographical locations. A growing awareness of diabetes preventative care, new product debuts, government efforts, and the CGM device market are the major market drivers for CGM Market.

Diabetes is a complicated, chronic condition that can lead to myocardial infarction, stroke, neuropathy, blindness, and renal damage. For patients to avoid aggravation and the beginning of problems, daily glucose level management is essential. With their recent development, real-time continuous glucose monitoring (CGM) apps have been created for smartphones and other devices connected to CGM systems. These CGM apps are also utilized in Japan. Using CGM applications enhances patients' blood glucose management as compared to conventional retrospective CGM, which is anticipated to aid in slowing the course of type 2 diabetes mellitus (DM) and preventing complications. Throughout the projected period, technological developments to increase sensor accuracy are anticipated to fuel market expansion.

Japan Continuous Glucose Monitoring Market Drivers:

  • The number of patients with Type-1 and Type-2 diabetes in Japan is expected to surge growth.

Type 1, also known as insulin-requiring diabetes, is brought on by immune system failure, whereas Type 2, sometimes referred to as insulin-dependent diabetes, is caused by adoption of a sedentary lifestyle. Type 2 diabetes is prevalent in Japan due to the senior population. To prevent various diseases, including renal issues, cardiovascular diseases, and other ailments, the blood glucose level is monitored using continuous glucose monitoring. Another explanation is that more people have had their illnesses identified after being referred to a hospital due to the findings of a metabolic syndrome screening.

  • CGM sensors are the prevailing factor for market growth.

CGM sensors are a prominent market shareholder. Hydrogen peroxide is formed when platinum reacts with glucose oxidase in the CGM sensor. Throughout the projected period, technological developments to increase sensor accuracy are anticipated to fuel market expansion. CGM has been a popular substitute for portable finger-prick glucometers, providing convenience to diabetic patients, which will upsurge the market in Japan.

Japan Continuous Glucose Monitoring Market Developments:

  • In December 2022, the Dexcom G6 CGM System now has increased payment coverage under the Japanese medical insurance system, according to a Terumo Company announcement. A larger population of patients with diabetes will be able to get reimbursement utilizing the Dexcom G6 CGM System in Japan, thanks to the recently created category of "C150."

  • In March 2022, the Japanese Ministry of Health, Labour, and Welfare gave the go-ahead for the FreeStyle® Libre system's reimbursement coverage to be expanded to encompass all diabetics who take insulin at least once per day, according to a statement released by Abbott.

Japan Continuous Glucose Monitoring (CGM) Market Scope:  

Report Metric Details
Total Market Size in 2026 USD 400.0 million
Total Market Size in 2031 USD 944.7 million
Forecast Unit Million
Growth Rate 18.8%
Study Period 2021 to 2031
Historical Data 2021 to 2024
Base Year 2025
Forecast Period 2026 – 2031
Segmentation Application, End-User Industry
Companies
  • Dexcom Inc.
  • Abbott Laboratories
  • Medtronic plc
  • Nipro Corporation
  • Panasonic Healthcare Co. Ltd.
  • Terumo Corporation
  • Roche Diabetes Care Inc.
  • Omron Healthcare Co. Ltd.
  • Fukuda Denshi Co. Ltd.
  • Arkray Inc.

Japan Continuous Glucose Monitoring (CGM) Market Segmentation:

  • By Application

    • Diabetes Patients

    • Critical Patients

  • By End-User Industry

    • Hospitals

    • Diagnostic Centers & Clinics

    • Home Care

Market Segmentation

By Application
  • Diabetes Patients
  • Critical Patients
By End-User Industry
  • Hospitals
  • Diagnostic Centers & Clinics
  • Home Care

Table of Contents

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. JAPAN CONTINUOUS GLUCOSE MONITORING (CGM) MARKET, BY APPLICATION

5.1. Introduction

5.2. Diabetes Patients

5.3. Critical Patients

6. JAPAN CONTINUOUS GLUCOSE MONITORING (CGM) MARKET, BY END-USER INDUSTRY

6.1. Introduction

6.2. Hospitals

6.3. Diagnostic Centers & Clinics

6.4. Home Care

7. COMPETITIVE ENVIRONMENT AND ANALYSIS

7.1. Major Players and Strategy Analysis

7.2. Emerging Players and Market Lucrativeness

7.3. Mergers, Acquisitions, Agreements, and Collaborations

7.4. Vendor Competitiveness Matrix

8. COMPANY PROFILES

8.1. Dexcom, Inc.

8.2. Abbott Laboratories

8.3. Medtronic plc

8.4. Nipro Corporation

8.5. Panasonic Healthcare Co., Ltd.

8.6. Terumo Corporation

8.7. Roche Diabetes Care, Inc.

8.8. Omron Healthcare Co., Ltd.

8.9. Fukuda Denshi Co., Ltd.

8.10. Arkray, Inc.

Need Assistance?

Our research team is available to answer your questions.

Contact Us
Report IDKSI061615168
PublishedMar 2026
Pages85
FormatPDF, Excel, PPT, Dashboard
Frequently Asked Questions

The Japan Continuous Glucose Monitoring (CGM) market is forecast to exhibit strong growth, with a Compound Annual Growth Rate (CAGR) of 18.8%. This growth is expected to lead the market from a valuation of USD 400.0 million in 2026 to reach USD 944.7 million by 2031.

Key market drivers include growing awareness of diabetes preventative care, the introduction of new products, and supportive government efforts. Additionally, technological advancements to increase sensor accuracy and the increasing prevalence of both Type 1 and Type 2 diabetes, particularly among Japan's senior population, are significant contributors to market expansion.

CGM sensors are identified as a prominent market shareholder, with their underlying technology involving hydrogen peroxide formation through the reaction of platinum with glucose oxidase. Furthermore, real-time continuous glucose monitoring (CGM) applications for smartphones and other devices are enhancing patients' blood glucose management, aiding in slowing the course of type 2 diabetes mellitus.

CGM systems have broad applications across various healthcare settings in Japan, including hospital ICUs, diagnostic centers, and clinics. They are designed for all age groups, with particular importance for the increasing number of patients diagnosed with Type 1 and Type 2 diabetes, especially the senior population where Type 2 diabetes is prevalent.

The market is anticipated to be fueled by ongoing technological developments aimed at increasing sensor accuracy throughout the projected period. Moreover, CGMS-based technologies are providing a blueprint for closed-loop bionic/artificial pancreas systems, prompting businesses that manufacture glucose monitoring devices to concentrate on creating novel and cutting-edge CGMS.

The rising number of patients with Type 1 and Type 2 diabetes in Japan is a major growth driver for the CGM market. Type 2 diabetes, specifically prevalent in the senior population due to sedentary lifestyles, along with increased diagnoses from metabolic syndrome screenings, necessitates daily glucose level management. CGM is crucial for these patients to avoid aggravation and prevent severe complications such as renal issues, cardiovascular diseases, and neuropathy.

Need data specifically for your business?Request Custom Research →
Related Reports

Trusted by the world's leading organizations

Weber Shandwick
veolia
Tri
tls
TeamViewer
GE Healthcare
Intel
Proctor and Gamble
ABB
Elkem
Defense Logistics Agency
Amazon